Huatai Chenguang Pharmaceutical announced that it has received $8,918,200 in funding led by Jiangsu Haisheng Investment Management Co., Ltd. on September 10, 2020. The transaction included participation from CSC Financial Co., Ltd, Jiangsu Addor Equity Investment Fund Management Co., Ltd., and BGI Genomics Co., Ltd.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
38.08 CNY | -0.96% | -1.45% | -20.67% |
Mar. 01 | BGI Genomics' 2023 Profit Falls 89% as Revenue Plunges 38% | MT |
Feb. 29 | BGI Genomics Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-20.67% | 2.02B | |
-17.60% | 11.52B | |
+39.11% | 3.27B | |
-29.30% | 1.44B | |
+11.45% | 1.01B | |
-6.33% | 719M | |
-30.75% | 418M | |
-51.02% | 339M | |
-2.58% | 284M | |
+25.57% | 240M |
- Stock Market
- Equities
- 300676 Stock
- News BGI Genomics Co., Ltd.
- Huatai Chenguang Pharmaceutical announced that it has received $8.9182 million in funding from CSC Financial Co., Ltd., Jiangsu Addor Equity Investment Fund Management Co., Ltd., Jiangsu Haisheng Investment Management Co., Ltd., BGI Genomics Co., Ltd.